Our Research Impact Overview
We are committed to support high quality research that has an impact at a local, national and global level.
For REF2021 we have submitted 18 impact case studies across three UoAs. Below are some examples whereas the detailed list can be read at the following page.
Primary human papillomavirus testing
Since 2003, Cuzick FRS and his team have driven the decision to replace cytological with the primary human papilloma virus (HPV) screening. As a result, HPV cervical screening are recommended in the 2015 European Guidelines and are introduced around the world. HPV primary screening in the NHS may prevent ~600 new cases of cervical cancer every year.
Chronic Hepatitis C
Foster has led pivotal trials for therapeutic treatment of hepatitis C virus (HCV) leading to new policy, the largest NHS investment in specialist services and with 22 networks managing >50,000 patients. In 2019, Public Health England quantified a fall in deaths and transplants due to HCV of 16% and 53%, respectively. This work addresses the WHO target to eliminate HCV by 2030.
Major Trauma Haemorrhage
Brohi has elucidated the mechanisms of trauma-induced coagulopathy, that is why patients succumb to organ failure after severe injury. His team developed a damage control resuscitation strategy, including a massive haemorrhage protocol or ‘Code Red’, adopted by all 23 major-trauma centres in England. At Barts NHS Trauma Centre, this implementation reduced bleeding mortality rates by 20.5% in 2014-2017.
DIALOG+, an Effective Intervention for Mental Health Care
Our WHO Social Mental Health Unit (Priebe, Bird) has developed the DIALOG+ intervention, an app used by patients for self-assessment. DIALOG patient ratings are now recommended for evaluation of care in all early intervention teams in England (18k patients as of October 2020 [NHS Digital]). The intervention has been translated in >17 languages, and implemented in over 18 countries.
The World’s First ‘Smart’ Toothpaste
Bioactive glasses developed by Hill has led to the spin out of BioMin Technologies Ltd. BioMinF® toothpaste is based on these glass particles, which form fluorapatite to protect teeth from decay and reduce sensitivity and pain. Six clinical trials show that BioMinF® is twice as more effective than other leading sensitivity toothpastes. BioMinF® containing toothpastes are now sold in >30 countries worldwide.
In the run-up to REF2021, we have established a Research Impact Team, led by the Deputy Dean for Research Impact, Professor Stephanie Taylor. The Impact Team is still operative to satisfy our intention to develop impact well beyond REF2021.